10x Genomics Statistics
Total Valuation
10x Genomics has a market cap or net worth of $3.01 billion. The enterprise value is $2.55 billion.
Important Dates
The last earnings date was Thursday, May 7, 2026, after market close.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
10x Genomics has 126.96 million shares outstanding. The number of shares has increased by 4.06% in one year.
| Current Share Class | 116.88M |
| Shares Outstanding | 126.96M |
| Shares Change (YoY) | +4.06% |
| Shares Change (QoQ) | +0.95% |
| Owned by Insiders (%) | 7.82% |
| Owned by Institutions (%) | 96.31% |
| Float | 115.09M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.71 |
| Forward PS | 4.82 |
| PB Ratio | 3.75 |
| P/TBV Ratio | 4.01 |
| P/FCF Ratio | 24.61 |
| P/OCF Ratio | 23.52 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.99 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 20.85 |
Financial Position
The company has a current ratio of 5.90, with a Debt / Equity ratio of 0.10.
| Current Ratio | 5.90 |
| Quick Ratio | 5.25 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | n/a |
| Debt / FCF | 0.67 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -2.98% and return on invested capital (ROIC) is -5.11%.
| Return on Equity (ROE) | -2.98% |
| Return on Assets (ROA) | -4.48% |
| Return on Invested Capital (ROIC) | -5.11% |
| Return on Capital Employed (ROCE) | -7.63% |
| Weighted Average Cost of Capital (WACC) | 15.12% |
| Revenue Per Employee | $542,261 |
| Profits Per Employee | -$19,233 |
| Employee Count | 1,178 |
| Asset Turnover | 0.67 |
| Inventory Turnover | 3.02 |
Taxes
In the past 12 months, 10x Genomics has paid $3.41 million in taxes.
| Income Tax | 3.41M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +184.62% in the last 52 weeks. The beta is 2.05, so 10x Genomics's price volatility has been higher than the market average.
| Beta (5Y) | 2.05 |
| 52-Week Price Change | +184.62% |
| 50-Day Moving Average | 21.70 |
| 200-Day Moving Average | 17.61 |
| Relative Strength Index (RSI) | 57.39 |
| Average Volume (20 Days) | 2,829,566 |
Short Selling Information
The latest short interest is 16.25 million, so 12.80% of the outstanding shares have been sold short.
| Short Interest | 16.25M |
| Short Previous Month | 16.47M |
| Short % of Shares Out | 12.80% |
| Short % of Float | 14.12% |
| Short Ratio (days to cover) | 6.57 |
Income Statement
In the last 12 months, 10x Genomics had revenue of $638.78 million and -$22.66 million in losses. Loss per share was -$0.18.
| Revenue | 638.78M |
| Gross Profit | 445.11M |
| Operating Income | -68.80M |
| Pretax Income | -19.25M |
| Net Income | -22.66M |
| EBITDA | -30.67M |
| EBIT | -68.80M |
| Loss Per Share | -$0.18 |
Full Income StatementBalance Sheet
The company has $539.85 million in cash and $81.39 million in debt, with a net cash position of $458.46 million or $3.61 per share.
| Cash & Cash Equivalents | 539.85M |
| Total Debt | 81.39M |
| Net Cash | 458.46M |
| Net Cash Per Share | $3.61 |
| Equity (Book Value) | 814.32M |
| Book Value Per Share | 6.31 |
| Working Capital | 556.14M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $127.82 million and capital expenditures -$5.64 million, giving a free cash flow of $122.18 million.
| Operating Cash Flow | 127.82M |
| Capital Expenditures | -5.64M |
| Depreciation & Amortization | 38.13M |
| Net Borrowing | n/a |
| Free Cash Flow | 122.18M |
| FCF Per Share | $0.96 |
Full Cash Flow StatementMargins
Gross margin is 69.68%, with operating and profit margins of -10.77% and -3.55%.
| Gross Margin | 69.68% |
| Operating Margin | -10.77% |
| Pretax Margin | -3.01% |
| Profit Margin | -3.55% |
| EBITDA Margin | -4.80% |
| EBIT Margin | -10.77% |
| FCF Margin | 19.13% |
Dividends & Yields
10x Genomics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.06% |
| Shareholder Yield | -4.06% |
| Earnings Yield | -0.75% |
| FCF Yield | 4.06% |
Analyst Forecast
The average price target for 10x Genomics is $25.23, which is 6.55% higher than the current price. The consensus rating is "Buy".
| Price Target | $25.23 |
| Price Target Difference | 6.55% |
| Analyst Consensus | Buy |
| Analyst Count | 16 |
| Revenue Growth Forecast (5Y) | 9.92% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
10x Genomics has an Altman Z-Score of 4.3 and a Piotroski F-Score of 4.
| Altman Z-Score | 4.3 |
| Piotroski F-Score | 4 |
